We are live on ! Find out more
RS

R Squared Portfolio holdings

AUM $182M
1-Year Est. Return 18.52%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+18.52%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$214M
AUM Growth
-$18.4M
Cap. Flow
-$18M
Cap. Flow %
-8.42%
Top 10 Hldgs %
15.12%
Holding
759
New
222
Increased
150
Reduced
140
Closed
246

Top Buys

Rank Stock Value
1
BLK icon
Blackrock
BLK
+$3.58M
2
EA icon
Electronic Arts
EA
+$3.45M
3
MSI icon
Motorola Solutions
MSI
+$3.41M
4
FYBR
Frontier Communications
FYBR
+$2.34M
5
TSM icon
TSMC
TSM
+$2.33M

Top Sells

Rank Stock Value
1
HON icon
Honeywell
HON
+$2.7M
2
K
Kellanova
K
+$2.67M
3
KO icon
Coca-Cola
KO
+$2.47M
4
SCHW
Charles Schwab
SCHW
+$2.47M
5
ED icon
Consolidated Edison
ED
+$2.22M

Sector Composition

Rank Sector Weight
1 Financials 19.27%
2 Technology 18.98%
3 Industrials 15.12%
4 Healthcare 10.83%
5 Communication Services 8.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WTI icon
476
W&T Offshore
WTI
$583M
$35.3K 0.02%
21,641
-37,700
-64% -$72.4K
AMC icon
477
AMC Entertainment Holdings
AMC
$1.95B
$34.8K 0.02%
22,280
+580
+3% +$1.38K
GEVO icon
478
Gevo
GEVO
$426M
$32.1K 0.02%
16,031
-5,680
-26% -$12.5K
POWW icon
479
Outdoor Holding Co
POWW
$250M
$31.8K 0.01%
+18,579
New +$31.9K
MVST icon
480
Microvast
MVST
$302M
$31.1K 0.01%
11,106
-3,484
-24% -$14.6K
GUTS icon
481
Fractyl Health
GUTS
$121M
$30.8K 0.01%
13,979
+3,356
+32% +$5.4K
EDIT icon
482
Editas Medicine
EDIT
$416M
$29.4K 0.01%
14,365
-6,260
-30% -$18.1K
PLX icon
483
Protalix BioTherapeutics
PLX
$188M
$26.3K 0.01%
+14,632
New +$29.9K
CCCC icon
484
C4 Therapeutics
CCCC
$408M
$26.1K 0.01%
13,674
-4,206
-24% -$9.96K
MGNX icon
485
MacroGenics
MGNX
$263M
$25.6K 0.01%
+15,891
New +$25K
HUMA icon
486
Humacyte
HUMA
$175M
$25.1K 0.01%
+26,153
New +$37K
ALIT icon
487
Alight
ALIT
$492M
$24.3K 0.01%
+623
New +$31K
NOTE
488
DELISTED
FiscalNote
NOTE
$23.1K 0.01%
+15,681
New +$47.7K
XTIA icon
489
XTI Aerospace
XTIA
$57.3M
$22.6K 0.01%
+18,210
New +$26.7K
AGIG
490
Abundia Global Impact Group
AGIG
$48.9M
$22.6K 0.01%
+11,389
New +$45.8K
REI icon
491
Ring Energy
REI
$333M
$21.9K 0.01%
25,152
+11,644
+86% +$11.1K
BNGO icon
492
Bionano Genomics
BNGO
$13M
$21.1K 0.01%
+13,771
New +$23.8K
LUCD icon
493
Lucid Diagnostics
LUCD
$181M
$20.1K 0.01%
+18,439
New +$20.6K
ALEC icon
494
Alector
ALEC
$167M
$19.5K 0.01%
+12,474
New +$22.1K
SPWH icon
495
Sportsman's Warehouse
SPWH
$45.3M
$18K 0.01%
12,303
-4,145
-25% -$9.01K
OCGN icon
496
Ocugen
OCGN
$423M
$17.8K 0.01%
+13,217
New +$18.8K
DSX icon
497
Diana Shipping
DSX
$280M
$17.6K 0.01%
+10,620
New +$18.5K
BIOX icon
498
Bioceres Crop Solutions
BIOX
$21.1M
$17K 0.01%
+12,940
New +$20.7K
ATOS icon
499
Atossa Therapeutics
ATOS
$25.3M
$16.6K 0.01%
+1,873
New +$23.7K
TCRX icon
500
TScan Therapeutics
TCRX
$57.1M
$16K 0.01%
16,033
-2,794
-15% -$4.04K

Similar funds

R Squared's Q4 2025 Portfolio in Review

As of Q4 2025, R Squared held 759 positions worth $214M, down 7.9% from $232M the previous quarter. Its ten largest holdings account for 15% of the portfolio.

R Squared withdrew a net $18M in Q4 2025, closing 246 positions and reducing 140 holdings. Its most notable exit was Honeywell, an estimated $2.7M position sold in full.

By sector, the portfolio is most concentrated in Financials at 19% of assets, down from 19% a quarter earlier, followed by Technology and Industrials.

Against the trend, R Squared opened a new position in Blackrock worth $3.51M.

  • R Squared's largest Q4 2025 buy was Blackrock: 3,276 shares worth $3.51M.
  • R Squared added most to Frontier Communications in Q4 2025, an estimated $2.34M increase.
  • R Squared's biggest Q4 2025 reduction was Charles Schwab, cutting an estimated $2.47M.
  • R Squared fully exited Honeywell in Q4 2025, selling an estimated $2.7M.
  • R Squared's ten largest holdings make up 15% of its $214M portfolio in Q4 2025.
  • R Squared opened 222 new positions and closed 246 in Q4 2025.
  • R Squared's portfolio value fell 7.9% quarter-over-quarter to $214M.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.